Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $13.86 Consensus Price Target from Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have earned a consensus rating of “Hold” from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $13.8571.

BCYC has been the topic of several research reports. Needham & Company LLC reduced their price target on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Citigroup reaffirmed a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th.

Insiders Place Their Bets

In other news, CEO Kevin Lee sold 5,905 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the sale, the chief executive officer owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. This represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 9,977 shares of company stock worth $42,702 in the last quarter. Insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. GSK plc bought a new position in shares of Bicycle Therapeutics in the fourth quarter worth about $10,829,000. Schroder Investment Management Group purchased a new stake in Bicycle Therapeutics during the fourth quarter worth $3,976,000. Renaissance Technologies LLC lifted its stake in shares of Bicycle Therapeutics by 72.8% during the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock worth $4,544,000 after purchasing an additional 412,700 shares during the last quarter. Woodline Partners LP bought a new stake in shares of Bicycle Therapeutics in the 1st quarter valued at about $3,088,000. Finally, Birchview Capital LP grew its holdings in Bicycle Therapeutics by 200.5% in the fourth quarter. Birchview Capital LP now owns 462,700 shares of the company’s stock worth $3,276,000 after purchasing an additional 308,700 shares during the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $4.30 on Wednesday. The stock has a market capitalization of $300.96 million, a price-to-earnings ratio of -1.58 and a beta of 1.54. Bicycle Therapeutics has a 12-month low of $3.74 and a 12-month high of $9.16. The stock’s 50-day moving average price is $4.16 and its 200-day moving average price is $4.54.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The firm had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. As a group, research analysts predict that Bicycle Therapeutics will post -2.26 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.